Professor Lenzo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First Patient Receives Antibody-based Prostate Cancer Treatment TLX591

The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer.

Nat lenzoColin haywardDrug administrationTelix pharmaceuticalsNational cancer instituteGenesiscare groupTelix pharmaceuticals limitedProfessor lenzoProstate cancer

Telix Initiates ProstACT Study with First Prostate Cancer Patient Dosed

Telix Initiates ProstACT Study with First Prostate Cancer Patient Dosed
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Colin haywardTelix pharmaceuticalsGod hospital murdochProfessor lenzo

Telix Pharmaceuticals Limited: First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Telix Pharmaceuticals Limited: First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesColin haywardNat lenzoGenesiscare group clinicalTelix pharmaceuticalsCompany phaseGenesiscare contract research organisationAustralian securities exchangeHealth canadaDrug administrationAustralian therapeutic goods administrationTelix pharmaceuticals limited disclosure committeePrnewswire telix pharmaceuticals limitedPharmaceuticals limitedGod hospital murdoch

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan). TLX591 is a rADC composed of a high-specificity PSMA-targeting antibody, chelator linker, and cytotoxic lutetium (177Lu) payload. The PSMA-targeted monoclonal antibody (mAb) ap

United statesUnited kingdomNat lenzoColin haywardTelix pharmaceuticalsTelix pharmaceuticals limited disclosure committeeAustralian securities exchangeDrug administrationGenesiscare group clinicalGenesiscare contract research organisationHealth canadaAustralian therapeutic goods administrationGod hospital murdochGenesiscare group clinical director theranosticsPrincipal investigatorGroup chief medical officer